CompletedNCT02555150
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Medication studyAges 18–35United States
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.
- Listed locations
- CharlottesvilleSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateSeptember 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 40
- Sponsor
- Rhodes Pharmaceuticals, L.P.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT02555150
- Official title
Show the full official title
A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Recruitment & locations
CompletedCharlottesville
Questions about this study
Who is behind this study?
The study sponsor is Rhodes Pharmaceuticals, L.P.
Did this study involve medication?
Yes. The study involved medication, including PRC-063, lisdexamfetamine dimesylate and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)